Summary
Cerulean Pharma Inc (Cerulean), formerly Tempo Pharmaceuticals Inc is a developer of nanotechnology-based products to improve treatment options for people living with cancer. The company uses dynamic tumor targeting platform for creating nanoparticle drug conjugates to attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Its products include NDC with a camptothecin payload and NDC with a docetaxel payload. Cerulean’s NDC with a camptothecin payload provides the treatment of relapsed renal cell carcinoma, relapsed platinum-resistant ovarian cancer and non-metastatic rectal cancer. Its NDC with a docetaxel payload offers treatment for solid tumor malignancies. Cerulean is headquartered in Waltham, Massachusetts, the US.
Cerulean Pharma Inc (CERU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cerulean Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Cerulean Pharma Secures USD15 Million from Hercules Technology Growth Capital 10
Cerulean Pharma Raises US$13 Million In Venture Financing 11
Cerulean Pharma Secures US$15 Million In Series D Financing 11
Partnerships 12
Cerulean Pharma Enters into Partnership with Novartis 12
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 13
Cerulean Pharma Enters into Research Agreement with GOG Foundation 14
Equity Offering 15
Cerulean Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 15
Cerulean Pharma Raises USD40 Million in Public Offering of Shares 16
Cerulean Pharma Raises USD1 Million in Private Placement of Shares 18
Cerulean Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For US$67 Million 19
Asset Transactions 20
Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 20
NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 22
Acquisition 23
Cerulean Pharma and Dare Bioscience Combine in Reverse Takeover Transaction 23
Cerulean Pharma Inc - Key Competitors 25
Key Employees 26
Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Nov 03, 2016: Cerulean Reports Third Quarter 2016 Financial Results and Provides Corporate Update 28
Aug 04, 2016: Cerulean Reports Second Quarter 2016 Corporate Highlights and Financial Results 29
May 02, 2016: Cerulean Reports First Quarter 2016 Corporate Highlights and Financial Results 31
Mar 10, 2016: Cerulean Reports Fourth Quarter 2015 Corporate Highlights and Financial Results 33
Corporate Communications 35
Oct 26, 2016: Cerulean Announces Promotion of Scott Eliasof, PhD to Senior Vice President and Chief Scientific Officer 35
Aug 18, 2016: Cerulean Announces Reduction in Force 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cerulean Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cerulean Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cerulean Pharma Secures USD15 Million from Hercules Technology Growth Capital 10
Cerulean Pharma Raises US$13 Million In Venture Financing 11
Cerulean Pharma Secures US$15 Million In Series D Financing 11
Cerulean Pharma Enters into Partnership with Novartis 12
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 13
Cerulean Pharma Enters into Research Agreement with GOG Foundation 14
Cerulean Pharma Raises USD1 Million in First Tranche of Private Placement of Shares 15
Cerulean Pharma Raises USD40 Million in Public Offering of Shares 16
Cerulean Pharma Raises USD1 Million in Private Placement of Shares 18
Cerulean Pharma Completes Underwriters Exercise Of Over-Allotment Option Of IPO For US$67 Million 19
Novartis Institutes for BioMedical Research to Acquire Dynamic Tumor Targeting Platform Technology from Cerulean Pharma 20
NewLink Genetics Acquires CRLX101 and CRLX301 from Cerulean Pharma 22
Cerulean Pharma and Dare Bioscience Combine in Reverse Takeover Transaction 23
Cerulean Pharma Inc, Key Competitors 25
Cerulean Pharma Inc, Key Employees 26
Cerulean Pharma Inc, Subsidiaries 27List of Figures
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cerulean Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
